Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Identification of a Series of Quinazolinediones as Potent, Selective, Post-Entry Inhibitors of Human Respiratory Syncytial Virus (hRSV) via a Cell-Based High Throughput Screen and Chemical Optimization.

Noah JW, Severson WE, Chung DH, Moore B, Jia F, Xu X, Maddox C, Rasmussen L, Sosa MI, Tower NA, Ananthan S, Evans CW, White EL, Jonsson C, Matharu DS, Flaherty DP, Simpson DS, Golden JE, Aubé J.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Dec 16 [updated 2013 Feb 28].

2.

A Cell Based HTS Approach for the Discovery of New Inhibitors of RSV.

Noah JW, Severson W, Chung DH, Moore B, Jia F, Xu X, Maddox C, Rasmussen L, Sosa MI, Tower NA, Ananthan S, White EL, Jonsson C, Matharu DS, Golden JE, Prisinzano TE, Aubé J.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Apr 15 [updated 2013 Feb 28].

3.

A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus.

Chung DH, Moore BP, Matharu DS, Golden JE, Maddox C, Rasmussen L, Sosa MI, Ananthan S, White EL, Jia F, Jonsson CB, Severson WE.

Virol J. 2013 Jan 10;10:19. doi: 10.1186/1743-422X-10-19.

4.

Benzimidazole analogs inhibit respiratory syncytial virus G protein function.

Evans CW, Atkins C, Pathak A, Gilbert BE, Noah JW.

Antiviral Res. 2015 Sep;121:31-8. doi: 10.1016/j.antiviral.2015.06.016.

PMID:
26116756
5.

Optimization of potent and selective quinazolinediones: inhibitors of respiratory syncytial virus that block RNA-dependent RNA-polymerase complex activity.

Matharu DS, Flaherty DP, Simpson DS, Schroeder CE, Chung D, Yan D, Noah JW, Jonsson CB, White EL, Aubé J, Plemper RK, Severson WE, Golden JE.

J Med Chem. 2014 Dec 26;57(24):10314-28. doi: 10.1021/jm500902x.

6.

(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.

Moore BP, Chung DH, Matharu DS, Golden JE, Maddox C, Rasmussen L, Noah JW, Sosa MI, Ananthan S, Tower NA, White EL, Jia F, Prisinzano TE, Aubé J, Jonsson CB, Severson WE.

J Med Chem. 2012 Oct 25;55(20):8582-7. doi: 10.1021/jm300612z.

7.

A Phenotypic High-Throughput Screen with RSV-Infected Primary Human Small Airway Epithelial Cells (SAECs).

Gobel J, Gartland M, Gurley SH, Kadwell S, Gillie D, Moore C, Goetz A.

J Biomol Screen. 2015 Jul;20(6):729-38. doi: 10.1177/1087057115580271.

PMID:
25862685
8.

Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.

Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.

J Manag Care Pharm. 2010 Jan-Feb;16(1):15-22.

10.

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P.

Ir Med J. 2000 Dec;93(9):284.

PMID:
11209917
11.

Respiratory syncytial virus: the virus, the disease and the immune response.

Ogra PL.

Paediatr Respir Rev. 2004;5 Suppl A:S119-26. Review.

PMID:
14980256
12.

WITHDRAWN: Immunoglobulin treatment for respiratory syncytial virus infection.

Fuller HL, Del Mar CB.

Cochrane Database Syst Rev. 2010 Sep 8;(9):CD004883. doi: 10.1002/14651858.CD004883.pub3. Review.

PMID:
20824840
13.
14.

Screening and evaluation of anti-respiratory syncytial virus compounds in cultured cells.

Lundin A, Bergström T, Trybala E.

Methods Mol Biol. 2013;1030:345-63. doi: 10.1007/978-1-62703-484-5_27.

PMID:
23821281
15.

High-Throughput Hit Screening Cascade to Identify Respiratory Syncytial Virus (RSV) Inhibitors.

Plant H, Stacey C, Tiong-Yip CL, Walsh J, Yu Q, Rich K.

J Biomol Screen. 2015 Jun;20(5):597-605. doi: 10.1177/1087057115569428.

PMID:
25656237
16.

Immunoglobulin treatment for respiratory syncytial virus infection.

Fuller H, Del Mar C.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004883. Review. Update in: Cochrane Database Syst Rev. 2010;(9):CD004883.

PMID:
17054220
17.

Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens.

Yan D, Weisshaar M, Lamb K, Chung HK, Lin MZ, Plemper RK.

Biochemistry. 2015 Sep 15;54(36):5589-604. doi: 10.1021/acs.biochem.5b00623.

18.

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.

J Mol Biol. 2007 May 4;368(3):652-65.

PMID:
17362988
19.

Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.

Rodriguez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EA, Meissner HC, Hemming VG, Hall CB, Lepow ML, Rosas AJ, Robertsen C, Kramer AA.

Pediatrics. 1997 Mar;99(3):454-61.

PMID:
9041304
20.

Respiratory syncytial virus bronchiolitis : current and future strategies for treatment and prophylaxis.

Chávez-Bueno S, Mejías A, Welliver RC.

Treat Respir Med. 2006;5(6):483-94.

PMID:
17154675
Items per page

Supplemental Content

Support Center